Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 5 studies | 22% ± 5% | |
epithelial cell | 4 studies | 34% ± 8% | |
astrocyte | 4 studies | 26% ± 7% | |
oligodendrocyte precursor cell | 4 studies | 24% ± 6% | |
fibroblast | 3 studies | 20% ± 1% | |
ciliated cell | 3 studies | 16% ± 1% | |
GABAergic neuron | 3 studies | 41% ± 1% | |
glutamatergic neuron | 3 studies | 47% ± 3% | |
dendritic cell | 3 studies | 24% ± 4% | |
basal cell | 3 studies | 30% ± 6% | |
endothelial cell | 3 studies | 19% ± 2% | |
microglial cell | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 1160.72 | 328 / 328 | 100% | 35.56 | 178 / 178 |
esophagus | 100% | 1423.70 | 1444 / 1445 | 100% | 32.01 | 183 / 183 |
thymus | 100% | 1551.43 | 653 / 653 | 100% | 53.65 | 604 / 605 |
prostate | 100% | 1507.76 | 245 / 245 | 100% | 47.63 | 501 / 502 |
ovary | 100% | 1635.08 | 180 / 180 | 100% | 34.92 | 429 / 430 |
breast | 100% | 1773.13 | 459 / 459 | 100% | 47.35 | 1115 / 1118 |
bladder | 100% | 1466.10 | 21 / 21 | 100% | 37.79 | 502 / 504 |
lung | 100% | 1371.58 | 576 / 578 | 100% | 30.69 | 1154 / 1155 |
uterus | 100% | 1503.39 | 170 / 170 | 100% | 37.22 | 457 / 459 |
intestine | 100% | 1270.38 | 966 / 966 | 99% | 35.80 | 521 / 527 |
stomach | 100% | 1417.40 | 359 / 359 | 99% | 32.31 | 282 / 286 |
brain | 98% | 919.08 | 2600 / 2642 | 100% | 32.28 | 705 / 705 |
liver | 100% | 852.77 | 226 / 226 | 98% | 20.28 | 398 / 406 |
skin | 100% | 1792.80 | 1809 / 1809 | 98% | 31.83 | 461 / 472 |
kidney | 100% | 1486.53 | 89 / 89 | 98% | 26.17 | 880 / 901 |
adrenal gland | 100% | 1842.97 | 258 / 258 | 96% | 25.13 | 221 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 35.19 | 29 / 29 |
spleen | 100% | 1579.89 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 34.44 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 25.94 | 1 / 1 |
adipose | 100% | 1604.44 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1339.14 | 1331 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 28.40 | 77 / 80 |
peripheral blood | 96% | 1212.91 | 893 / 929 | 0% | 0 | 0 / 0 |
heart | 89% | 529.08 | 769 / 861 | 0% | 0 | 0 / 0 |
muscle | 88% | 440.35 | 708 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006103 | Biological process | 2-oxoglutarate metabolic process |
GO_0070189 | Biological process | kynurenine metabolic process |
GO_0097053 | Biological process | L-kynurenine catabolic process |
GO_0009058 | Biological process | biosynthetic process |
GO_0006520 | Biological process | amino acid metabolic process |
GO_0005739 | Cellular component | mitochondrion |
GO_0005737 | Cellular component | cytoplasm |
GO_0016212 | Molecular function | kynurenine-oxoglutarate transaminase activity |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0047804 | Molecular function | cysteine-S-conjugate beta-lyase activity |
GO_0047315 | Molecular function | kynurenine-glyoxylate transaminase activity |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | KYAT3 |
Protein name | Alternative protein CCBL2 Kynurenine--oxoglutarate transaminase 3 (EC 2.6.1.63) (EC 2.6.1.7) (EC 4.4.1.13) (Cysteine-S-conjugate beta-lyase 2) (Kynurenine aminotransferase 3) (Kynurenine aminotransferase III) (Kynurenine--glyoxylate transaminase) (Kynurenine--oxoglutarate transaminase III) Kynurenine--oxoglutarate transaminase 3 (EC 2.6.1.7) (Cysteine-S-conjugate beta-lyase 2) (EC 4.4.1.13) (Kynurenine aminotransferase 3) (Kynurenine aminotransferase III) (KATIII) (Kynurenine--glyoxylate transaminase) (EC 2.6.1.63) (Kynurenine--oxoglutarate transaminase III) |
Synonyms | KAT3 CCBL2 |
Description | FUNCTION: Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid (KA), an intermediate in the tryptophan catabolic pathway which is also a broad spectrum antagonist of the three ionotropic excitatory amino acid receptors among others. May catalyze the beta-elimination of S-conjugates and Se-conjugates of L-(seleno)cysteine, resulting in the cleavage of the C-S or C-Se bond. Has transaminase activity towards L-kynurenine, tryptophan, phenylalanine, serine, cysteine, methionine, histidine, glutamine and asparagine with glyoxylate as an amino group acceptor (in vitro). Has lower activity with 2-oxoglutarate as amino group acceptor (in vitro). . |
Accessions | ENST00000370491.7 [Q6YP21-3] ENST00000370486.1 ENST00000260508.9 [Q6YP21-1] Q6YP21 L0R594 A0A0A0MRN7 |